A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs STNM 01 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Stelic Institute & Co
- 01 Nov 2017 Primary endpoint (Improvement of endoscopic lesions with respect to Mucosal healing by Mayo Endoscopic Subscore: STNM01 (250 nM) group versus placebo group) has been met, according to results presented at the 25th United European Gastroenterology Week.
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week.
- 27 Jul 2016 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History